To facilitate pharmaceutical companies users of the "IMS - Scientific Representatives" Online Service, some clarifications on the advertising of medicines to healthcare professionals governed by Title VIII of Legislative Decree 219/2006 are provided in the form of Questions & Answers.
This document cancels and replaces the similar ones published on the AIFA Portal on 10 February 2013 and 22 June 2016.
AIFA – Published on: 03 May 2023
Questions & Answers relating to the Online Service "IMS - Scientific Representatives" [0.61Mb] [PDF]
Medical-scientific information
Through the dissemination of independent information, AIFA intends to promote the safe and appropriate use of medicines, directing the therapeutic choices of doctors on the basis of scientific evidence (EBM) for the protection of patients. The intent is to establish itself as the main authoritative source of news and updates on pharmaceutical matters, both as regards the more strictly regulatory activities and those pertaining to the promotion of a new drug culture, based on ethics and transparency.
The Scientific Information Office is responsible for verifying and monitoring the Promotional Materials deposited with AIFA by Pharmaceutical Companies, in compliance with the provisions of Legislative Decree 219/2006 regarding Medical-Scientific Information.
Among the information tools that AIFA makes available to patients and healthcare professionals is the Independent Drug Information Center with a series of explanatory documents that will gradually be published on the portal on specific topics; in addition, a direct line with users (patients and healthcare professionals) has been provided thanks to the Pharmaceuticals-line service.
Reference offices
Scientific Information Office
Cynthia Berghella
c.berghella@aifa.gov.itinfomedicoscientifica@aifa.gov.it
Related articles: AIFA. Updating of the IMS Front End User Manual relating to the Scientific Representatives Form and the Deposit of Promotional Material
